There has been an uproar over the exposure of Mylan Pharmaceutical raising the cost of EpiPens over 500% since the company acquired rights for the drug in 2007. These anti-anaphalaxis injection devices spiked to a cost of $600 for a two pack, prompting an exasperated mother to exclaim that her family no longer had a college fund but were saving to pay for Epipens.
From a public policy perspective, it is worth considering if EpiPen is an example of how crony capitalism injects price gouging.
- Mylan's exclusivity was beginning to erode but the FDA blocked Teva Pharmaceutical's generic alternative by requesting more data. In addition, Sanofi Pharmaceutical withdrew Auvi-Q because of dosing concerns. So EpiPen had a virtual monopoly thru 2017
- Under the School Access to Emergency Epinephrine Law (2013), the federal government offers states a financial incentive for schools to stock EpiPens.,
- Mylan's CEO Heather Bresch is the daughter of West Virginia Senator Joe Manchin (D-WV), who has been conspicuously silent about the EpiPen outrage
- Mylan Pharmaceuticals has been a significant foreign corporate contributor to the Clinton Foundation and has partnered with the Clinton Foundation since 2009.
One of the consequences of Obamacare is that many heath insurance consumers are being forced into high deductible health plans, meant that consumers could not qualify for volume formulary discounts.
More and more it seems that there is a nexus between requiring Americans under Obamacare into having high deductible insurance and pharmaceutical profits.
The only remedies seem to be public outrage aimed at the District of Calamity to alleviate outrages or wait for a total collapse of the Obamacare insurance system.
More and more it seems that there is a nexus between requiring Americans under Obamacare into having high deductible insurance and pharmaceutical profits.
The only remedies seem to be public outrage aimed at the District of Calamity to alleviate outrages or wait for a total collapse of the Obamacare insurance system.
No comments:
Post a Comment